S&P 500   0.72 (+6.87%)
DOW   0.72 (+6.87%)
QQQ   271.86 (+2.52%)
AAPL   452.04 (+3.32%)
MSFT   209.19 (+2.86%)
FB   259.89 (+1.47%)
GOOGL   1,507.24 (+1.80%)
AMZN   3,162.24 (+2.65%)
NVDA   457.61 (+5.44%)
CGC   17.25 (+1.77%)
BABA   255.19 (+2.73%)
TSLA   1,554.76 (+13.12%)
GE   6.72 (-0.15%)
MU   48.48 (+1.51%)
AMD   82.61 (+7.45%)
T   30.18 (-0.07%)
F   7.11 (-1.66%)
ACB   9.80 (-2.20%)
GILD   68.84 (+1.09%)
NFLX   475.47 (+1.83%)
DIS   131.79 (+1.00%)
BAC   26.73 (-0.71%)
BA   175.44 (-2.60%)
S&P 500   0.72 (+6.87%)
DOW   0.72 (+6.87%)
QQQ   271.86 (+2.52%)
AAPL   452.04 (+3.32%)
MSFT   209.19 (+2.86%)
FB   259.89 (+1.47%)
GOOGL   1,507.24 (+1.80%)
AMZN   3,162.24 (+2.65%)
NVDA   457.61 (+5.44%)
CGC   17.25 (+1.77%)
BABA   255.19 (+2.73%)
TSLA   1,554.76 (+13.12%)
GE   6.72 (-0.15%)
MU   48.48 (+1.51%)
AMD   82.61 (+7.45%)
T   30.18 (-0.07%)
F   7.11 (-1.66%)
ACB   9.80 (-2.20%)
GILD   68.84 (+1.09%)
NFLX   475.47 (+1.83%)
DIS   131.79 (+1.00%)
BAC   26.73 (-0.71%)
BA   175.44 (-2.60%)
S&P 500   0.72 (+6.87%)
DOW   0.72 (+6.87%)
QQQ   271.86 (+2.52%)
AAPL   452.04 (+3.32%)
MSFT   209.19 (+2.86%)
FB   259.89 (+1.47%)
GOOGL   1,507.24 (+1.80%)
AMZN   3,162.24 (+2.65%)
NVDA   457.61 (+5.44%)
CGC   17.25 (+1.77%)
BABA   255.19 (+2.73%)
TSLA   1,554.76 (+13.12%)
GE   6.72 (-0.15%)
MU   48.48 (+1.51%)
AMD   82.61 (+7.45%)
T   30.18 (-0.07%)
F   7.11 (-1.66%)
ACB   9.80 (-2.20%)
GILD   68.84 (+1.09%)
NFLX   475.47 (+1.83%)
DIS   131.79 (+1.00%)
BAC   26.73 (-0.71%)
BA   175.44 (-2.60%)
S&P 500   0.72 (+6.87%)
DOW   0.72 (+6.87%)
QQQ   271.86 (+2.52%)
AAPL   452.04 (+3.32%)
MSFT   209.19 (+2.86%)
FB   259.89 (+1.47%)
GOOGL   1,507.24 (+1.80%)
AMZN   3,162.24 (+2.65%)
NVDA   457.61 (+5.44%)
CGC   17.25 (+1.77%)
BABA   255.19 (+2.73%)
TSLA   1,554.76 (+13.12%)
GE   6.72 (-0.15%)
MU   48.48 (+1.51%)
AMD   82.61 (+7.45%)
T   30.18 (-0.07%)
F   7.11 (-1.66%)
ACB   9.80 (-2.20%)
GILD   68.84 (+1.09%)
NFLX   475.47 (+1.83%)
DIS   131.79 (+1.00%)
BAC   26.73 (-0.71%)
BA   175.44 (-2.60%)
Log in

OTCMKTS:BICXBiocorrx Stock Price, Forecast & News

$2.73
+0.28 (+11.43 %)
(As of 08/13/2020 04:00 PM ET)
Add
Compare
Today's Range
$1.98
Now: $2.73
$2.73
50-Day Range
$2.46
MA: $2.65
$2.85
52-Week Range
$1.50
Now: $2.73
$4.02
Volume3,870 shs
Average Volume2,104 shs
Market Capitalization$14.69 million
P/E RatioN/A
Dividend YieldN/A
Beta1.4
BioCorRx, Inc. engages in the provision of alcoholism and opioid addiction treatment. It offers treatment philosophy that combines medical intervention and a proprietary cognitive behavioral therapy program specifically tailored for the treatment of alcoholism and other substance abuse addictions for those receiving long-term naltrexone treatment. It also engages in the research and development of sustained release naltrexone products for the treatment of addiction and other possible disorders. The company was founded by Neil Terrence Muller and George O'Neill on January 28, 2008 and is headquartered in Anaheim, CA.
Read More

Beat the Market (BTM) Rank

Analyst Opinion: 0.0Community Rank: 2.6Dividend Strength: 0.0Insider Behavior: 0.0Valuation: 0.0 5 -4 -3 -2 -1 -

Overall Beat the Market Rank

0.52 out of 5 stars


Industry, Sector and Symbol

Industry Specialty outpatient clinics, not elsewhere classified
Sub-IndustryN/A
SectorMedical
Current SymbolOTCMKTS:BICX
CUSIPN/A
Phone714-462-4880

Debt

Price-To-Earnings

Sales & Book Value

Annual Sales$240,000.00
Book Value($0.20) per share

Profitability

Net Income$-6,040,000.00
Net Margins-2,511.44%

Miscellaneous

EmployeesN/A
Market Cap$14.69 million
Next Earnings DateN/A
OptionableNot Optionable
$2.73
+0.28 (+11.43 %)
(As of 08/13/2020 04:00 PM ET)
30 days | 90 days | 365 days | Advanced Chart

Receive BICX News and Ratings via Email

Sign-up to receive the latest news and ratings for BICX and its competitors with MarketBeat's FREE daily newsletter.

speech bubbles
speech bubbles











Biocorrx (OTCMKTS:BICX) Frequently Asked Questions

How has Biocorrx's stock price been impacted by Coronavirus?

Biocorrx's stock was trading at $2.00 on March 11th, 2020 when Coronavirus reached pandemic status according to the World Health Organization (WHO). Since then, BICX stock has increased by 36.5% and is now trading at $2.73.
View which stocks have been most impacted by COVID-19
.

How were Biocorrx's earnings last quarter?

Biocorrx Inc (OTCMKTS:BICX) posted its earnings results on Friday, May, 15th. The company reported ($0.20) earnings per share for the quarter. The company earned $0.04 million during the quarter.
View Biocorrx's earnings history
.

Has Biocorrx been receiving favorable news coverage?

News coverage about BICX stock has trended extremely negative recently, InfoTrie reports. The research group scores the sentiment of news coverage by analyzing more than six thousand news and blog sources in real-time. The firm ranks coverage of public companies on a scale of -5 to 5, with scores nearest to five being the most favorable. Biocorrx earned a daily sentiment score of -4.1 on InfoTrie's scale. They also gave news stories about the company a news buzz of 10.0 out of 10, indicating that recent news coverage is extremely likely to have an effect on the company's share price in the next several days.
View the latest news about Biocorrx
.

Are investors shorting Biocorrx?

Biocorrx saw a decrease in short interest in the month of May. As of May 15th, there was short interest totaling 3,800 shares, a decrease of 44.9% from the April 30th total of 6,900 shares. Based on an average daily volume of 1,300 shares, the short-interest ratio is currently 2.9 days.
View Biocorrx's Short Interest
.

Who are some of Biocorrx's key competitors?

Some companies that are related to Biocorrx include Acadia Healthcare (ACHC), BioTelemetry (BEAT), Hanger (HNGR), IMAC (IMAC) and AAC (AAC).
View all competitors
.

What other stocks do shareholders of Biocorrx own?

Based on aggregate information from My MarketBeat watchlists, some companies that other Biocorrx investors own include Mondi (MNDI), Alkermes (ALKS), Editas Medicine (EDIT), ImmunoGen (IMGN), Intel (INTC), Netflix (NFLX), Nektar Therapeutics (NKTR), Oracle (ORCL), SS&C Technologies (SSNC) and AT&T (T).

Who are Biocorrx's key executives?

Biocorrx's management team includes the following people:
  • Brady James Granier, President Chief Executive Officer & Director
  • Lourdes Felix, Director, Chief Operating & Financial Officer
  • Kenneth Orbeck, Medical Director
  • Balbir S. Brar, Senior Vice President-Drug Development

What is Biocorrx's stock symbol?

Biocorrx trades on the OTCMKTS under the ticker symbol "BICX."

How do I buy shares of Biocorrx?

Shares of BICX can be purchased through any online brokerage account. Popular online brokerages with access to the U.S. stock market include Vanguard Brokerage Services, TD Ameritrade, E*TRADE, Robinhood, Fidelity, and Charles Schwab.

What is Biocorrx's stock price today?

One share of BICX stock can currently be purchased for approximately $2.73.

How big of a company is Biocorrx?

Biocorrx has a market capitalization of $14.69 million and generates $240,000.00 in revenue each year.

What is Biocorrx's official website?

The official website for Biocorrx is www.biocorrx.com.

How can I contact Biocorrx?

Biocorrx's mailing address is 2390 EAST ORANGEWOOD AVENUE SUITE 575, ANAHEIM CA, 92806. The company can be reached via phone at 714-462-4880 or via email at [email protected]

This page was last updated on 8/13/2020 by MarketBeat.com Staff

Enter your email address below to receive a concise daily summary of analysts' upgrades, downgrades and new coverage with MarketBeat.com's FREE daily email newsletter.